- Home
- IOVA vs DVAX Comparison
IOVA vs DVAX Comparison
Compare IOVA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- DVAX
- Stock Information
- Founded
- IOVA 2007
- DVAX 1996
- Country
- IOVA United States
- DVAX United States
- Employees
- IOVA N/A
- DVAX N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- IOVA Health Care
- DVAX Health Care
- Exchange
- IOVA Nasdaq
- DVAX Nasdaq
- Market Cap
- IOVA 771.4M
- DVAX N/A
- IPO Year
- IOVA N/A
- DVAX 2004
- Fundamental
- Price
- IOVA $1.71
- DVAX $9.91
- Analyst Decision
- IOVA Buy
- DVAX Buy
- Analyst Count
- IOVA 10
- DVAX 4
- Target Price
- IOVA $12.22
- DVAX $26.25
- AVG Volume (30 Days)
- IOVA 11.8M
- DVAX 1.8M
- Earning Date
- IOVA 08-07-2025
- DVAX 08-05-2025
- Dividend Yield
- IOVA N/A
- DVAX N/A
- EPS Growth
- IOVA N/A
- DVAX N/A
- EPS
- IOVA N/A
- DVAX N/A
- Revenue
- IOVA $212,679,000.00
- DVAX $294,620,000.00
- Revenue This Year
- IOVA $86.62
- DVAX $21.18
- Revenue Next Year
- IOVA $69.95
- DVAX $16.83
- P/E Ratio
- IOVA N/A
- DVAX N/A
- Revenue Growth
- IOVA 11070.12
- DVAX 24.76
- 52 Week Low
- IOVA $1.64
- DVAX $9.22
- 52 Week High
- IOVA $12.51
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- IOVA 36.89
- DVAX 45.65
- Support Level
- IOVA $1.95
- DVAX $9.65
- Resistance Level
- IOVA $2.47
- DVAX $10.68
- Average True Range (ATR)
- IOVA 0.16
- DVAX 0.34
- MACD
- IOVA -0.00
- DVAX 0.00
- Stochastic Oscillator
- IOVA 6.41
- DVAX 25.24
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.